Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

An estimated 828 million adults (420 women, 408 men) had diabetes in 2022, an increase of 630 million since 1990. India (212 ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...